About Us

Cardivia Labs Inc. is a biotechnology company pioneering RNA-based therapeutics to reverse vascular aging and treat atherosclerosis. We develop target-site blockers (TSBs) and antisense oligonucleotides (ASOs) to modulate protective genes and silence pathogenic ones, effectively restoring youthful vascular function.

The Opportunity

Cardiovascular disease remains the leading global cause of death.
More than 80% of adults over 60 have some degree of vascular aging or atherosclerosis.
Delaying vascular aging by even one year could save billions and improve quality of life for millions.

Our Science

We target key endothelial chemokine receptors and restore protective epigenetic regulators such as SIRT6 and TET2. Our RNA medicines address the fundamental biology of vascular aging and atherosclerosis.

A New Approach

Programmable RNA medicines

We employ LNA-based TSBs and ASOs to disrupt microRNA repression, enhance beneficial gene expression, and prevent vascular injury. Our development is biomarker-led and aligned with clinical translation.

TSBs: lift microRNA-mediated repression to enhance protective genes (e.g., CXCR4, SIRT6, TET2).
ASOs: silence pro-inflammatory / atherogenic transcripts (e.g., CXCR2).

Illustration of Cardivia’s RNA-based approach

Our Focus

CXCR4-TSB

Enhances CXCR4 expression, strengthening vascular integrity and reducing plaque formation.

CXCR2-ASO

Silences atherogenic genes to treat plaque and improve serum lipid profile.

SIRT6-TBS

Restores SIRT6 activity to reverse vascular aging.

TET2-TBS

Boosts TET2 activity—paired with OSK overexpression—to rejuvenate vascular cells and reduce chronic inflammation.

Pipeline

Program	Target	Modality	Primary Indication	Status
CXCR4-TSB	CXCR4	TSB (LNA)	Atherosclerosis	IND-enabling planned
SIRT6-TBS	SIRT6	TSB (LNA)	Vascular aging	Discovery → Preclinical
OSK + TET2-TBS	TET2 and OSK	TSB (LNA)	Vascular aging	Discovery → Preclinical
CXCR2-ASO	CXCR2	ASO (LNA)	Atherosclerosis	Discovery

Team

Cardivia Labs is led by scientists and entrepreneurs with deep expertise in RNA therapeutics, vascular biology, and cardiovascular drug development.

News

Check back soon for press releases and media coverage.

Join Us

We welcome collaborators and talent passionate about RNA therapeutics and cardiovascular health. Email careers@cardivialabs.com to explore opportunities.

Contact

Partnering & Scientific

Email: hello@cardivialabs.com

Rochester, NY • USA

Message Us

Add a Squarespace form block or embed your contact form here.